亨廷顿舞蹈症治疗方法获批。 - Suppr

Suppr

超能文献

Treatment for Hunter syndrome approved.

出版信息

FDA Consum. 2006 Sep-Oct;40(5):4.

PMID:17328099

Abstract

摘要

相似文献

Treatment for Hunter syndrome approved.

FDA Consum. 2006 Sep-Oct;40(5):4.

First treatment for Hunter syndrome.

FDA Consum. 2006 Nov-Dec;40(6):5.

Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.

Prescrire Int. 2008 Jun;17(95):109.

Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.

Pediatr Dermatol. 2012 May-Jun;29(3):369-70. doi: 10.1111/j.1525-1470.2011.01418.x. Epub 2011 Oct 13.

Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.

Eur J Med Genet. 2008 May-Jun;51(3):268-71. doi: 10.1016/j.ejmg.2008.02.005. Epub 2008 Mar 4.

Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.

Mol Genet Metab. 2007 Jun;91(2):183-90. doi: 10.1016/j.ymgme.2007.03.003. Epub 2007 Apr 24.

Idursulfase for the treatment of mucopolysaccharidosis II.

Expert Opin Pharmacother. 2008 Feb;9(2):311-7. doi: 10.1517/14656566.9.2.311.

Show drugs work before selling them.

Nature. 2017 Mar 8;543(7644):174-175. doi: 10.1038/543174a.

Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.

Acta Paediatr. 2008 Apr;97(457):76-8. doi: 10.1111/j.1651-2227.2008.00661.x.

[Early response to idursulfase in a 31-year old male patient with Hunter syndrome].

Rev Clin Esp. 2011 Jul-Aug;211(7):e42-5. doi: 10.1016/j.rce.2011.01.014. Epub 2011 Apr 27.

引用本文的文献

A novel iduronate 2-sulfatase mutation in a Chinese family with mucopolysaccharidosis type II.

World J Pediatr. 2012 Aug;8(3):281-3. doi: 10.1007/s12519-012-0357-1. Epub 2012 May 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Treatment for Hunter syndrome approved.

FDA Consum. 2006 Sep-Oct;40(5):4.

First treatment for Hunter syndrome.

FDA Consum. 2006 Nov-Dec;40(6):5.

Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.

Prescrire Int. 2008 Jun;17(95):109.

Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.

Pediatr Dermatol. 2012 May-Jun;29(3):369-70. doi: 10.1111/j.1525-1470.2011.01418.x. Epub 2011 Oct 13.

Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.

Eur J Med Genet. 2008 May-Jun;51(3):268-71. doi: 10.1016/j.ejmg.2008.02.005. Epub 2008 Mar 4.

Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.

Mol Genet Metab. 2007 Jun;91(2):183-90. doi: 10.1016/j.ymgme.2007.03.003. Epub 2007 Apr 24.

Idursulfase for the treatment of mucopolysaccharidosis II.

Expert Opin Pharmacother. 2008 Feb;9(2):311-7. doi: 10.1517/14656566.9.2.311.

Show drugs work before selling them.

Nature. 2017 Mar 8;543(7644):174-175. doi: 10.1038/543174a.

Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.

Acta Paediatr. 2008 Apr;97(457):76-8. doi: 10.1111/j.1651-2227.2008.00661.x.

[Early response to idursulfase in a 31-year old male patient with Hunter syndrome].

Rev Clin Esp. 2011 Jul-Aug;211(7):e42-5. doi: 10.1016/j.rce.2011.01.014. Epub 2011 Apr 27.

引用本文的文献

A novel iduronate 2-sulfatase mutation in a Chinese family with mucopolysaccharidosis type II.

World J Pediatr. 2012 Aug;8(3):281-3. doi: 10.1007/s12519-012-0357-1. Epub 2012 May 23.